Review: The Pharmacology of Dobutamine

Ruffolo, Robert

doi:10.1097/00000441-198710000-00005

Cited by 309 publications

(145 citation statements)

References 20 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Although (±)-dobutamine is used clinically and is administered by intravenous infusion (Ruffolo, 1987), when we came to devise the protocols for the present work we discovered that surprisingly little is known about the full haemodynamic profile of this drug during prolonged constant infusion either in man (Ruffolo, 1987;Leier et al, 1977;1978;Sonnenblick et al, 1979) or in experimental animals (Liang & Hood, 1979). Thus, while a considerable literature on (±)-dobutamine exists, in large part it relates to bolus injections, brief infusions or incremental infusions of the drug (e.g.…”

Section: Introductionmentioning

confidence: 84%

“…cardiac) and 12-(i.e. hindquarters, Gardiner & Bennett, 1988) adrenoceptor-stimulating properties, although reflex responses to the increased cardiac output may have contributed to changes in regional vascular conductance (Ruffolo & Messick, 1985b;Ruffolo, 1987).…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, none of the experiments performed so far have compared either rat or human a-CGRP to an established drug, such as (±)-dobutamine, which is used clinically for its ability to improve cardiac function (Ruffolo, 1987;Marcus et al, 1987). The primary aim of the present work was, therefore, to measure the cardiac haemodynamic effects of intravenous infusions of two doses of human a-CGRP and to compare them with the effects of infusions of (±)-dobutamine in the same animals.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Differential effects of (±)‐dobutamine and human α‐CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats

Gardiner

Compton

Kemp

et al. 1991

British J Pharmacology

View full text Add to dashboard Cite

1 Comparisons were made of the full haemodynamic profiles of the known cardiostimulant, (± )-dobutamine, and the putative inotropic peptide, human a-calcitonin gene-related peptide (human a-CGRP), in conscious, chronically-instrumented Long Evans rats. Both substances were administered continuously i.v. for 60min at two doses ((±)-dobutamine, 2 and lOpmolkgr'h-i; human a-CGRP, 0.15 and 1.5 nmol kg1 h 1). 2 In spite of their similar (small) effects on mean arterial blood pressure, the low doses of (±)-dobutamine and human a-CGRP influenced cardiac haemodynamics differently. Thus, (±)-dobutamine caused an increase in cardiac index (due to a tachycardia), accompanied by rises in peak aortic flow, maximum rate of rise of aortic flow (dF/dtmai) and total peripheral conductance. However, the latter waned during the infusion, and after the infusion there was a significant systemic vasoconstriction and reductions in peak aortic flow, dF/dtmax and stroke index. Such 'off' effects following dobutamine infusion have not been described previously. The infusion of the lower dose of human cx-CGRP caused only a transient fall in central venous pressure.3 The rise in total peripheral conductance during infusion of the lower dose of (±)-dobutamine was associated with increases in hindquarters and common and internal carotid vascular conductances. The fall in total peripheral conductance after infusion was associated with renal vasoconstriction. Although there was no significant change in total peripheral conductance during the infusion of the lower dose of human a-CGRP there were hindquarters and carotid vasodilatations together with mesenteric vasoconstriction. 4 Infusion of the higher dose of ( )-dobutamine had greater effects than the lower dose on all cardiac haemodynamic variables and additionally, increased stroke index. However, the negative cardiac haemodynamic effects following the offset of infusion were also enhanced in association with marked renal and mesenteric vasoconstrictions. While infusion of the higher dose of human a-CGRP increased cardiac index, peak aortic flow, dF/dtmax and total peripheral conductance, stroke index fell together with central venous pressure. 5 (±)-Dobutamine caused greater cardiostimulation and increases in hindquarters blood flow than did human a-CGRP. However, the latter at the higher dose caused substantially greater common and internal carotid hyperaemia than did (±)-dobutamine, possibly indicating a selective and additional effect of human a-CGRP on cranial blood flow. Furthermore, there were no adverse cardiovascular effects following infusion of human a-CGRP.

show abstract

Section: Introductionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential effects of (±)‐dobutamine and human α‐CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats

Gardiner

Compton

Kemp

et al. 1991

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…On the other hand, dobutamine is associated with a variable decrease in peripheral vascular resistance, mediated through β2 peripheral adrenergic and dopaminergic vascular receptors, resulting in peripheral vasodilatation. This could explain an increased FVD due to dobutamine treatment (23)(24)(25). However, some of our children also received dopamine.…”

Section: Discussionmentioning

confidence: 87%

“…Its most important effect results from peripheral vasoconstriction, an effect derived from stimulating peripheral α1/α2 adrenergic and dopaminergic receptors. This effect could be further intensified by dobutamine (23)(24)(25). Therefore, one would expect a reduced FVD in the skin.…”

Section: Discussionmentioning

confidence: 99%

Microcirculatory mechanisms in postnatal hypotension affecting premature infants

et al. 2013

View full text Add to dashboard Cite

Clinical Utility of Digital Dobutamine Stress Echocardiography in the Noninvasive Evaluation of Coronary Artery Disease

Madu

Ahmar²,

Arthur³

et al. 1994

Arch Intern Med

View full text Add to dashboard Cite

Exercise electrocardiography is an established mode of evaluation for patients with suspected coronary artery disease. It also provides prognostic information and guides therapeutic management in patients with established disease. However, some patients are unable to exercise because of orthopedic problems, neurologic diseases, peripheral vascular disease, or deconditioning. In the past, these patients have been referred for angiography to help assess their disease. Recently, however, new techniques to assess myocardial perfusion and/or function, including stress echocardiography, have been used in the noninvasive assessment of coronary artery disease in this group of patients. Echocardiography has been used in combination with different drugs, including dobutamine, dipyridamole, and adenosine. Dobutamine is probably the single most studied drug for stress echocardiography. Dobutamine stress echocardiography is a safe, feasible, and valuable technique for evaluating coronary artery disease.

show abstract

Review: The Pharmacology of Dobutamine

Cited by 309 publications

References 20 publications

Differential effects of (±)‐dobutamine and human α‐CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats

Differential effects of (±)‐dobutamine and human α‐CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats

Microcirculatory mechanisms in postnatal hypotension affecting premature infants

Clinical Utility of Digital Dobutamine Stress Echocardiography in the Noninvasive Evaluation of Coronary Artery Disease

Contact Info

Product

Resources

About